PriceTargets.com logo

Cassava Sciences - FLNA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $5.00
  • Forecasted Upside: 278.79%
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.32 As of 06/5/2026 05:00 PM ET
+0 (0.00%)

This chart shows the closing price for FLNA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cassava Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FLNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FLNA

Analyst Price Target is $5.00
▲ +278.79% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Cassava Sciences in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 278.79% upside from the last price of $1.32.

This chart shows the closing price for FLNA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 2 contributing investment analysts is to hold stock in Cassava Sciences. This rating changed within the last month from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/15/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/15/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/10/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/10/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/9/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/8/2026

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/26/2026Maxim GroupReiterated RatingBuy$5.00
4/22/2026Weiss RatingsDowngradeSell (D-) ➝ Sell (E+)
12/26/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/30/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
3/25/2025HC WainwrightReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.00
3/4/2025HC WainwrightReiterated RatingNeutral ➝ Neutral
11/26/2024HC WainwrightDowngradeBuy ➝ Neutral$116.00
11/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$116.00 ➝ $116.00
10/8/2024HC WainwrightUpgradeNeutral ➝ Buy$116.00
8/13/2024HC WainwrightReiterated RatingNeutral
8/8/2024Rodman & RenshawReiterated RatingBuy ➝ Buy$107.00 ➝ $107.00
7/19/2024HC WainwrightReiterated RatingNeutral
7/1/2024HC WainwrightDowngradeBuy ➝ Neutral
5/17/2024HC WainwrightBoost TargetBuy ➝ Buy$124.00 ➝ $131.00
3/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$124.00
8/8/2023HC WainwrightReiterated RatingBuy ➝ Buy$88.57
3/6/2023HC WainwrightReiterated RatingBuy$88.57
1/25/2023B. Riley FinancialLower Target$31.43 ➝ $20.00
1/24/2023HC WainwrightReiterated RatingBuy$88.57
11/29/2022Univest SecLower Target$8.57 ➝ $7.86
11/16/2022B. Riley FinancialDowngradeBuy ➝ Neutral$31.43
11/8/2022Univest SecBoost TargetSell ➝ Sell$5.71 ➝ $8.57
8/11/2022B. Riley FinancialLower TargetBuy$41.43 ➝ $31.43
8/4/2022HC WainwrightReiterated RatingBuy
5/6/2022B. Riley FinancialLower Target$51.43 ➝ $41.43
5/5/2022B. Riley FinancialReiterated RatingBuy
4/4/2022Univest SecInitiated CoverageSell
1/24/2022B. Riley FinancialLower TargetBuy$77.14 ➝ $51.43
9/3/2021JonesTradingReiterated RatingBuy$153.57
8/25/2021JonesTradingReiterated RatingBuy$153.57
8/3/2021B. Riley FinancialBoost TargetBuy$79.29 ➝ $103.57
7/20/2021HC WainwrightBoost TargetPositive ➝ Buy$69.29 ➝ $88.57
7/15/2021Cantor FitzgeraldDowngradeOverweight ➝ Neutral$71.43
6/23/2021B. Riley FinancialBoost TargetBuy$55.71 ➝ $79.29
(Data available from 6/8/2021 forward)

News Sentiment Rating

0.97 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/10/2025
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/10/2025
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/9/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/8/2026
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/10/2026
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/9/2026
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2026
  • 2 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2026

Current Sentiment

  • 2 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

  • No positive mentions tracked during this time.

Very Positive

Cassava Sciences logo
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
Read More

Today's Range

Now: $1.32
Low: $1.29
High: $1.38

50 Day Range

MA: $1.51
Low: $1.18
High: $1.83

52 Week Range

Now: $1.32
Low: $1.16
High: $4.98

Volume

326,065 shs

Average Volume

360,446 shs

Market Capitalization

$63.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Cassava Sciences?

The following Wall Street analysts have issued research reports on Cassava Sciences in the last year: Maxim Group, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for FLNA.

What is the current price target for Cassava Sciences?

0 Wall Street analysts have set twelve-month price targets for Cassava Sciences in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 278.8%. Maxim Group has the highest price target set, predicting FLNA will reach $5.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $5.00 for Cassava Sciences in the next year.
View the latest price targets for FLNA.

What is the current consensus analyst rating for Cassava Sciences?

Cassava Sciences currently has 1 sell rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in FLNA, but not buy more shares or sell existing shares.
View the latest ratings for FLNA.

What other companies compete with Cassava Sciences?

Other companies that are similar to Cassava Sciences include Niagen Bioscience, Zentalis Pharmaceuticals, Alpha Teknova, Eledon Pharmaceuticals and Surrozen. Learn More about companies similar to Cassava Sciences.

How do I contact Cassava Sciences' investor relations team?

Cassava Sciences' physical mailing address is 6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX, 78731. The company's listed phone number is 512-501-2444 and its investor relations email address is [email protected]. The official website for Cassava Sciences is www.filanatx.com. Learn More about contacing Cassava Sciences investor relations.